LEXG-Lexicon Genetics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : LEXG-Lexicon Genetics

LXRX 1.390

+3.7%

Oct 31 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: rkrw who started this subject	11/11/2003 8:19:59 AM
From: nigel bates	Read Replies (1) of 254

Lexicon Achieves First Performance Milestone in Genentech Alliance THE WOODLANDS, Texas, Nov. 10 /PRNewswire-FirstCall/ -- Lexicon Genetics Incorporated (Nasdaq: LEXG - News) announced today the completion of the first performance milestone as part of its drug discovery alliance with Genentech, Inc. (NYSE: DNA - News). "We are very pleased with the progress that we have achieved so far under this alliance," said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Lexicon. "This milestone represents a key first step in the combination of Genentech's product portfolio of therapeutic proteins with Lexicon's industrial in vivo drug discovery capabilities to discover the medical value of these important therapeutic proteins." Lexicon established its drug discovery alliance with Genentech in December 2002 to discover novel therapeutic proteins and antibody targets. Under the alliance agreement, Lexicon is using its target validation technologies to discover the functions of secreted proteins and potential antibody targets identified through Genentech's drug discovery research. Genentech will have certain exclusive and non-exclusive rights for the research, development and commercialization of therapeutic proteins and antibodies resulting from the collaboration. Lexicon will retain certain other rights to those discoveries, including non-exclusive rights for the development and commercialization of small molecule drugs. Lexicon received an up-front payment and is entitled to receive performance payments for its work in the collaboration as it is completed. This milestone has triggered such a performance payment, the amount of which is not disclosed. Lexicon is also entitled to receive milestone payments and royalties on net sales of therapeutic proteins and antibodies for which Genentech obtains exclusive rights.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next